{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:13:50Z","timestamp":1791220430077,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,12,29]],"date-time":"2010-12-29T00:00:00Z","timestamp":1293580800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s10549-010-1316-y","type":"journal-article","created":{"date-parts":[[2010,12,28]],"date-time":"2010-12-28T08:48:31Z","timestamp":1293526111000},"page":"109-117","source":"Crossref","is-referenced-by-count":54,"title":["Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)"],"prefix":"10.1007","volume":"126","author":[{"given":"A.","family":"Noske","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Darb-Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kronenwett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. M.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"von Toerne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Wirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. T.","family":"Grasshoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. U.","family":"Ulmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Denkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"von Minckwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,12,29]]},"reference":[{"key":"1316_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.humpath.2004.01.002","volume":"35","author":"H Yaziji","year":"2004","unstructured":"Yaziji H, Gown AM (2004) Accuracy and precision in her2\/neu testing in breast cancer: are we there yet? Hum Pathol 35:143\u2013146","journal-title":"Hum Pathol"},{"key":"1316_CR2","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2002.09.094","volume":"20","author":"MF Press","year":"2002","unstructured":"Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L (2002) Evaluation of her-2\/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20:3095\u20133105","journal-title":"J Clin Oncol"},{"key":"1316_CR3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1200\/JCO.2001.19.2.354","volume":"19","author":"A Lebeau","year":"2001","unstructured":"Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, Untch M, Lohrs U (2001) Her-2\/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19:354\u2013363","journal-title":"J Clin Oncol"},{"key":"1316_CR4","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/modpathol.3880440","volume":"14","author":"TA Thomson","year":"2001","unstructured":"Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, Dupuis B, Parker RL (2001) Her-2\/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 14:1079\u20131086","journal-title":"Mod Pathol"},{"issue":"Suppl 2","key":"1316_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/modpathol.2008.34","volume":"21","author":"AM Gown","year":"2008","unstructured":"Gown AM (2008) Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 21(Suppl 2):8\u201315","journal-title":"Mod Pathol"},{"key":"1316_CR6","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJMc0801440","volume":"358","author":"S Paik","year":"2008","unstructured":"Paik S, Kim C, Wolmark N (2008) Her2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358:1409\u20131411","journal-title":"N Engl J Med"},{"key":"1316_CR7","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/sj.bjc.6604769","volume":"99","author":"AK Koutras","year":"2008","unstructured":"Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G, Zografos G, Timotheadou E, Papakostas P, Linardou H, Razis E, Economopoulos T, Kalofonos HP, Fountzilas G (2008) Evaluation of the prognostic and predictive value of her family mRNA expression in high-risk early breast cancer: a hellenic cooperative oncology group (HECOG) study. Br J Cancer 99:1775\u20131785","journal-title":"Br J Cancer"},{"key":"1316_CR8","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1373\/clinchem.2008.122572","volume":"55","author":"K Bohmann","year":"2009","unstructured":"Bohmann K, Hennig G, Rogel U, Poremba C, Mueller BM, Fritz P, Stoerkel S, Schaefer KL (2009) RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. Clin Chem 55:1719\u20131727","journal-title":"Clin Chem"},{"key":"1316_CR9","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/jnci\/djn089","volume":"100","author":"G Minckwitz von","year":"2008","unstructured":"von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M (2008) Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 100:552\u2013562","journal-title":"J Natl Cancer Inst"},{"key":"1316_CR10","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/jnci\/djn085","volume":"100","author":"G Minckwitz von","year":"2008","unstructured":"von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M (2008) Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 100:542\u2013551","journal-title":"J Natl Cancer Inst"},{"key":"1316_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10549-010-1103-9","volume":"124","author":"J Huober","year":"2010","unstructured":"Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Hogel B, Darb-Esfahani S, Mehta K, Loibl S (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124:133\u2013140","journal-title":"Breast Cancer Res Treat"},{"key":"1316_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-006-9253-5","volume":"100","author":"DF Hayes","year":"2006","unstructured":"Hayes DF, Ethier S, Lippman ME (2006) New guidelines for reporting of tumor marker studies in breast cancer research and treatment: remark. Breast Cancer Res Treat 100:237\u2013238","journal-title":"Breast Cancer Res Treat"},{"key":"1316_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10549-006-9242-8","volume":"100","author":"LM McShane","year":"2006","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) Reporting recommendations for tumor marker prognostic studies (remark). Breast Cancer Res Treat 100:229\u2013235","journal-title":"Breast Cancer Res Treat"},{"key":"1316_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American society of clinical oncology\/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118\u2013145","journal-title":"J Clin Oncol"},{"key":"1316_CR15","doi-asserted-by":"publisher","first-page":"R69","DOI":"10.1186\/bcr2363","volume":"11","author":"S Darb-Esfahani","year":"2009","unstructured":"Darb-Esfahani S, Loibl S, Muller BM, Roller M, Denkert C, Komor M, Schluns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G (2009) Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline\/taxane-based chemotherapy. Breast Cancer Res 11:R69","journal-title":"Breast Cancer Res"},{"key":"1316_CR16","doi-asserted-by":"crossref","unstructured":"M\u00fcller BM (2009) Quantitative determination of predictive cancer biomarkers in formalin-fixed, paraffin-embedded tissue using a new fully automated method for RNA isolation. J Clin Oncol 27 (suppl, abstr 11032)","DOI":"10.1200\/jco.2009.27.15_suppl.11032"},{"key":"1316_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2353\/jmoldx.2009.080070","volume":"11","author":"AA Iverson","year":"2009","unstructured":"Iverson AA, Gillett C, Cane P, Santini CD, Vess TM, Kam-Morgan L, Wang A, Eisenberg M, Rowland CM, Hessling JJ, Broder SE, Sninsky JJ, Tutt A, Anderson S, Chang SY (2009) A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimens. J Mol Diagn 11:117\u2013130","journal-title":"J Mol Diagn"},{"key":"1316_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/path.1523","volume":"202","author":"C Ginestier","year":"2004","unstructured":"Ginestier C, Charafe-Jauffret E, Penault-Llorca F, Geneix J, Adelaide J, Chaffanet M, Mozziconacci MJ, Hassoun J, Viens P, Birnbaum D, Jacquemier J (2004) Comparative multi-methodological measurement of ERBB2 status in breast cancer. J Pathol 202:286\u2013298","journal-title":"J Pathol"},{"key":"1316_CR19","doi-asserted-by":"publisher","first-page":"8348","DOI":"10.1158\/1078-0432.CCR-05-0841","volume":"11","author":"U Vinatzer","year":"2005","unstructured":"Vinatzer U, Dampier B, Streubel B, Pacher M, Seewald MJ, Stratowa C, Kaserer K, Schreiber M (2005) Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-pcr as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Clin Cancer Res 11:8348\u20138357","journal-title":"Clin Cancer Res"},{"key":"1316_CR20","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1200\/JCO.2005.02.6187","volume":"24","author":"M Kaufmann","year":"2006","unstructured":"Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, von Minckwitz G (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24:1940\u20131949","journal-title":"J Clin Oncol"},{"key":"1316_CR21","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N (2008) Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols b-18 and b-27. J Clin Oncol 26:778\u2013785","journal-title":"J Clin Oncol"},{"key":"1316_CR22","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1093\/annonc\/mdm201","volume":"18","author":"M Kaufmann","year":"2007","unstructured":"Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackesz R, Makris A, Miller W, Pierga JY, Semiglazov V, Schneeweiss A, Souchon R, Stearns V, Untch M, Loibl S (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18:1927\u20131934","journal-title":"Ann Oncol"},{"key":"1316_CR23","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.amjsurg.2009.06.004","volume":"198","author":"MC Tan","year":"2009","unstructured":"Tan MC, Al Mushawah F, Gao F, Aft RL, Gillanders WE, Eberlein TJ, Margenthaler JA (2009) Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg 198:520\u2013525","journal-title":"Am J Surg"},{"key":"1316_CR24","doi-asserted-by":"publisher","first-page":"6622","DOI":"10.1158\/1078-0432.CCR-04-0380","volume":"10","author":"M Colleoni","year":"2004","unstructured":"Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nole F, Peruzzotti G, Goldhirsch A (2004) Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10:6622\u20136628","journal-title":"Clin Cancer Res"},{"key":"1316_CR25","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275\u20131281","journal-title":"J Clin Oncol"},{"key":"1316_CR26","doi-asserted-by":"crossref","unstructured":"Huober J (2009) Neoadjuvant chemotherapy in operable breast cancer with docetaxel, doxorubicin, and cyclophosphamide (TAC) or TAC followed by vinorelbine and capecitabine (NX): final results and analysis of markers predicting response to treatment. J Clin Oncol 27 (suppl, abstr 524)","DOI":"10.1200\/jco.2009.27.15_suppl.524"},{"key":"1316_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.breast.2007.02.006","volume":"16","author":"A Rody","year":"2007","unstructured":"Rody A, Karn T, Solbach C, Gaetje R, Munnes M, Kissler S, Ruckhaberle E, Minckwitz GV, Loibl S, Holtrich U, Kaufmann M (2007) The ERBB2\u00a0+\u00a0cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GeparTrio trial. Breast 16:235\u2013240","journal-title":"Breast"},{"key":"1316_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10549-009-0329-x","volume":"119","author":"RL Jones","year":"2010","unstructured":"Jones RL, Salter J, A\u2019Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M (2010) Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 119:315\u2013323","journal-title":"Breast Cancer Res Treat"},{"key":"1316_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10549-006-9492-5","volume":"106","author":"E Arriola","year":"2007","unstructured":"Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS (2007) Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 106:181\u2013189","journal-title":"Breast Cancer Res Treat"},{"key":"1316_CR30","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1158\/1078-0432.CCR-04-2421","volume":"11","author":"R Rouzier","year":"2005","unstructured":"Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678\u20135685","journal-title":"Clin Cancer Res"},{"key":"1316_CR31","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","volume":"13","author":"LA Carey","year":"2007","unstructured":"Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329\u20132334","journal-title":"Clin Cancer Res"},{"key":"1316_CR32","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1200\/JCO.2005.02.6914","volume":"24","author":"V Guarneri","year":"2006","unstructured":"Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037\u20131044","journal-title":"J Clin Oncol"},{"key":"1316_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10549-007-9594-8","volume":"108","author":"F Andre","year":"2008","unstructured":"Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L (2008) HER2 expression and efficacy of preoperative paclitaxel\/FAC chemotherapy in breast cancer. Breast Cancer Res Treat 108:183\u2013190","journal-title":"Breast Cancer Res Treat"},{"key":"1316_CR34","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2009.25.9366","volume":"28","author":"A Lebeau","year":"2010","unstructured":"Lebeau A, Turzynski A, Braun S, Behrhof W, Fleige B, Schmitt WD, Grob TJ, Burkhardt L, Holzel D, Jackisch C, Thomssen C, Muller V, Untch M (2010) Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. J Clin Oncol 28:3264\u20133270","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1316-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-010-1316-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1316-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T10:22:03Z","timestamp":1637058123000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-010-1316-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,29]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["1316"],"URL":"https:\/\/doi.org\/10.1007\/s10549-010-1316-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,29]]}}}